Targeted Agent and Profiling Utilization Registry (TAPUR) Study
This study looks at how well specific targeted cancer drugs work for patients with advanced cancers that have specific genetic features. By matching treatments to the unique genetic makeup of a tumor, researchers hope to find better and more personalized options for people when standard treatments are no longer working.
This study is open to people aged 12 and older with advanced solid tumors, multiple myeloma, or B-cell non-Hodgkin lymphoma. Participants need to be well enough to handle daily activities and meet specific blood and health counts to ensure safety.
Participants will receive a targeted therapy or immunotherapy drug chosen specifically based on the genetic traits of their cancer. Doctors will closely monitor your health and how your cancer responds throughout the treatment process.
The study is currently recruiting patients at various medical centers, including locations in Alabama, Arizona, and California. You can join at a participating center near you.
- 1Tests targeted cancer therapies based on your tumor's unique genetic code.
- 2Open to patients 12 and older with advanced cancers where standard treatments are no longer working.
- 3Currently recruiting participants at multiple locations across the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.